Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
3.200
-0.040 (-1.23%)
At close: Oct 15, 2026, 4:00 PM EDT
3.210
+0.010 (0.31%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Relmada Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Relmada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.75. The average 1-year stock price forecast is 235.94% higher than the current stock price, while the lowest is $9.00 (+181.25%) and the highest is $12 (+275.00%).
Price Target: $10.75 (+235.94%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 10, 2026.
Analyst Ratings
The average analyst rating for Relmada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +275.00% | Aug 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +275.00% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.48
from -1.10
EPS Next Year
-0.56
from -0.48
EPS and Forward PE are based on non-GAAP adjusted numbers.